Fate Therapeutics initiated at Jefferies Fate Therapeutics initiated with a Buy at Jefferies. Jefferies analyst Amin started Fate Therapeutics with a Buy rating and $17 price target. Natural killer cells possess advantageous cytotoxic properties distinct from T cells, and have demonstrated clinical efficacy against select cancer types, Amin tells investors in a research note. The analyst says Fate “offers a unique and potentially disruptive approach.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.